Experts Highlight the Main Issue Facing the Russian Pharmaceutical Market in 2023
Dec. 28, 2022
The main issue for the domestic pharmaceutical market in 2023 will be the departure of foreign manufacturers and, consequently, a shortage of foreign products, experts interviewed by RIA Novosti have shared.
“In 2023, Russia will need many pharmaceutical products more than ever to replace those supplied by major international pharmaceutical companies that have left the market,” said Azamat Metov, General Director of the Russian pharmaceutical company Farm Aid.
He explained that this concerns modern monoclonal antibodies, biological and chemical drugs, anti-cancer therapies, vaccines, and other products. According to the expert, to address these needs, pharmaceutical manufacturers “will need to focus on domestic developments and the transfer of technology for the production of the necessary market drugs.”
Artem Sirazutdinov, General Director of the R&D laboratory System-BioTech (part of AFK Sistema), agrees with Metov. “The main challenge for the Russian medical research market, where demand will be actively growing, in 2023 will be the departure of foreign manufacturers of diagnostic reagents, components, and equipment used by domestic laboratories and clinics,” he notes.
“I am confident that 2023 will determine the direction and prospects for the development of the domestic pharmaceutical industry for many years to come. The healthcare system and patients will benefit from all these processes,” concluded Metov.